Michael Ruberson Ribeiro da Silva (Michael R Da Silva, Michael Ruberson Ribeiro Da Silva)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 20

Top Topics

Rheumatoid Arthritis

Metastatic Colorectal Cancer

Top Venues

International journal of environmental research and public health

Expert review of clinical immunology

Expert review of pharmacoeconomics & outcomes research

Advances in rheumatology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Patrícia Silva Bazoni, Ronaldo José Faria, Francisca Janiclecia Rezende Cordeiro, Élida da Silva Timóteo, Alciellen Mendes da Silva, Ana Luisa Horsth, Eduardo Frizzera Meira, Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva
Self-Medication during the COVID-19 Pandemic in Brazil: Findings and Implications to Promote the Rational Use of Medicines. International journal of environmental research and public health 20 (12) (2023)
Patrícia Silva Bazoni, Ronaldo José Faria, Francisca Janiclecia Rezende Cordeiro, Élida da Silva Timóteo, Alciellen Mendes da Silva, Ana Luisa Horsth, Eduardo Frizzera Meira, Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva
Self-Medication during the COVID-19 Pandemic in Brazil: Findings and Implications to Promote the Rational Use of Medicines. International journal of environmental research and public health 20 (12) (2023)
Patrícia Silva Bazoni, Ronaldo José Faria, Francisca Janiclecia Rezende Cordeiro, Élida da Silva Timóteo, Alciellen Mendes da Silva, Ana Luisa Horsth, Eduardo Frizzera Meira, Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva
Self-Medication during the COVID-19 Pandemic in Brazil: Findings and Implications to Promote the Rational Use of Medicines. International journal of environmental research and public health 20 (12) (2023)
Patrícia Silva Bazoni, Ronaldo José Faria, Francisca Janiclecia Rezende Cordeiro, Élida da Silva Timóteo, Alciellen Mendes da Silva, Ana Luisa Horsth, Eduardo Frizzera Meira, Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva
Self-Medication during the COVID-19 Pandemic in Brazil: Findings and Implications to Promote the Rational Use of Medicines. International journal of environmental research and public health 20 (12) (2023)
Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Adriana Maria Kakehasi, Alessandra Maciel Almeida, Pedro Ricardo Kömel Pimenta, Juliana Álvares Teodoro, Francisco de Assis Acurcio
First-line biologic therapy with tumor necrosis factor inhibitors for psoriatic arthritis: a prospective observational study. Sao Paulo medical journal = Revista paulista de medicina 140 (6) (2022)
Jéssica Barreto Ribeiro Dos Santos, Rosângela Maria Gomes, Michael Ruberson Ribeiro da Silva
Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience. Expert review of clinical immunology 18 (9) (2022)
Elisa Neide Barbosa de Souza, Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Edna Afonso Reis, Juliana Álvares Teodoro, Francisco de Assis Acurcio, Alessandra Maciel Almeida
Functionality assessment in patients with rheumatic diseases undergoing treatment in the Public Health System. Einstein (Sao Paulo, Brazil) 20 (2022)
Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva
TransCon human growth hormone for children with growth hormone deficiency: a technology evaluation. Expert opinion on drug delivery 19 (1) (2022)
Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva
Daridorexant for the treatment of insomnia disorder: findings and implications. European journal of clinical pharmacology 78 (11) (2022)
Pedro Ricardo Kömel Pimenta, Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Adriana Maria Kakehasi, Francisco de Assis Acurcio, Juliana Álvares Teodoro
Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study. Journal of comparative effectiveness research 10 (6) (2021)
Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Alessandra Maciel Almeida, Juliana Alvares-Teodoro, Francisco de Assis Acurcio
Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model. Expert review of pharmacoeconomics & outcomes research (2021)
Ana F Souza, Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Alessandra Maciel Almeida, Francisco de Assis Acurcio, Juliana Álvares Teodoro
Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study. Pharmacy practice 19 (2) (2021)
Francisco de Assis Acurcio, Augusto Afonso Guerra Junior, Michael Ruberson Ribeiro da Silva, Ramon Gonçalves Pereira, Brian B Godman, Marion Bennie, Hacene Nedjar, Elham Rahme
Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study. Current medical research and opinion 36 (4) (2020)
Haliton Alves de Oliveira Júnior, Tiago Pereira da Veiga, Francisco de Assis Acurcio, Alessandra Maciel Almeida, Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva, Adriana Maria Kakehasi, Mariângela Leal Cherchiglia
Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff. Hospital practice (1995) 48 (4) (2020)
Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva, Adriana Maria Kakehasi, Francisco de Assis Acurcio, Alessandra Maciel Almeida, Haliton Alves de Oliveira Júnior, Pedro Ricardo Kömel Pimenta, Juliana Alvares-Teodoro
FIRST LINE OF SUBCUTANEOUS ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS: A PROSPECTIVE COHORT STUDY. Expert review of clinical immunology 16 (12) (2020)
Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva, Alessandra Maciel Almeida, Francisco de Assis Acurcio, Juliana Álvares Teodoro
Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model. Expert review of pharmacoeconomics & outcomes research 21 (5) (2020)
Jéssica Barreto Ribeiro Dos Santos, Augusto Afonso Guerra Junior, Michael Ruberson Ribeiro da Silva, Alessandra Maciel Almeida, Francisco de Assis Acurcio, Juliana Álvares Teodoro
First line of biological drugs in rheumatoid arthritis: a medication persistence analysis. Expert review of clinical pharmacology 12 (4) (2019)
Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Alessandra Maciel Almeida, Augusto Afonso Guerra Junior, Juliana Álvares Teodoro, Francisco de Assis Acurcio
Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations. Expert review of clinical immunology 15 (8) (2019)
Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Alessandra Maciel Almeida, Juliana Alvares-Teodoro, Adriana Maria Kakehasi, Francisco de Assis Acurcio
Access to high-cost medications for psoriatic arthritis in the National Health System in Brazil: the long path up to dispensation. Advances in rheumatology (London, England) 59 (1) (2019)
Wânia Cristina da Silva, Vânia Eloisa de Araújo, Ellias Magalhães E Abreu Lima, Jéssica Barreto Ribeiro Dos Santos, Michael Ruberson Ribeiro da Silva, Paulo Henrique Ribeiro Fernandes Almeida, Francisco de Assis Acurcio, Brian B Godman, Amanj Baker Kurdi, Mariângela Leal Cherchiglia, Eli Iola Gurgel Andrade
Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 32 (6) (2019)